Daiichi Sankyo Company Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
18,726
- Stock Symbol
-
4568
- Investments
-
19
- Share Price
-
$25.35
- (As of Friday Closing)
Daiichi Sankyo Company General Information
Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Contact Information
Website
www.daiichisankyo.comCorporate Office
- 3-5-1, Nihonbashi-honcho
- Chuo-ku
- Tokyo, 103-8426
- Japan
Corporate Office
- 3-5-1, Nihonbashi-honcho
- Chuo-ku
- Tokyo, 103-8426
- Japan
Daiichi Sankyo Company Stock Performance
As of 07-Feb-2025, Daiichi Sankyo Company’s stock price is $25.35. Its current market cap is $47.7B with 1.88B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.35 | $25.23 | $24.93 - $43.18 | $47.7B | 1.88B | 4.91M | $0.85 |
Daiichi Sankyo Company Financials Summary
As of 31-Dec-2024, Daiichi Sankyo Company has a trailing 12-month revenue of $11.9B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 46,974,992 | 52,542,786 | 64,393,294 | 32,599,295 |
| Revenue | 11,858,738 | 11,085,126 | 9,443,498 | 9,300,888 |
| EBITDA | 2,195,165 | 1,878,464 | 1,391,250 | 1,169,630 |
| Net Income | 1,622,798 | 1,389,240 | 806,519 | 596,137 |
| Total Assets | 21,929,610 | 22,868,418 | 18,828,961 | 18,201,057 |
| Total Debt | 645,920 | 672,038 | 1,073,861 | 1,339,318 |
Daiichi Sankyo Company Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Daiichi Sankyo Company Comparisons
Industry
Financing
Details
Daiichi Sankyo Company Competitors (57)
One of Daiichi Sankyo Company’s 57 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Celldex Therapeutics | Formerly VC-backed | Hampton, NJ | ||||
| Genmab | Formerly VC-backed | Copenhagen, Denmark | ||||
| Immatics | Formerly VC-backed | Tuebingen, Germany | ||||
| Enzon Pharmaceuticals | Corporation | Cranford, NJ |
Daiichi Sankyo Company Patents
Daiichi Sankyo Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024172395-A | Respiratory syncytial virus vaccine and its use | Pending | 31-May-2023 | ||
| JP-2024133943-A | Glucuronosyltransferase | Pending | 20-Mar-2023 | ||
| AU-2023313120-A1 | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor | Pending | 28-Jul-2022 | ||
| AU-2023274540-A1 | Dosage regimen of an anti-cdh6 antibody-drug conjugate | Pending | 24-May-2022 | ||
| JP-2023164109-A | Polymer targeting l-type amino acid transporter 1 | Pending | 28-Apr-2022 |
Daiichi Sankyo Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Daiichi Sankyo Company Investments & Acquisitions (19)
Daiichi Sankyo Company’s most recent deal was a PIPE with Ultragenyx Pharmaceutical for . The deal was made on 31-Mar-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | 31-Mar-2020 | PIPE | Drug Discovery | ||
| Cuorips | 11-Jul-2018 | Seed Round | Drug Discovery | ||
| Glycotope (Global Rights to Develop Gatipotuzumab Antibody-Drug Conjugates) | 30-Jun-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Rice Force | 02-Oct-2015 | Merger/Acquisition | Personal Products | ||
| Ambit Biosciences | 11-Nov-2014 | Merger/Acquisition | Pharmaceuticals |
Daiichi Sankyo Company ESG
Risk Overview
Risk Rating
Updated November, 22, 2024
19.95 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 425
Rank
Percentile
Daiichi Sankyo Company Exits (10)
Daiichi Sankyo Company’s most recent exit was on 31-Mar-2020 from Ultragenyx Pharmaceutical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | 31-Mar-2020 | Completed |
|
||
| Cuorips | 11-Jul-2018 | Completed |
|
||
| Zenotech Laboratories | 01-Jan-2014 | Completed |
|
||
| Orphan Disease Treatment Institute | 14-Feb-2013 | Completed |
|
||
| Coherus Biosciences | 10-Mar-2011 | Early Stage VC | Completed |
|
Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| U3 Pharma | Planegg, Germany | 2001 | |
| American Regent | Shirley, NY | 1967 |
Daiichi Sankyo Company FAQs
-
When was Daiichi Sankyo Company founded?
Daiichi Sankyo Company was founded in 2005.
-
Where is Daiichi Sankyo Company headquartered?
Daiichi Sankyo Company is headquartered in Tokyo, Japan.
-
What is the size of Daiichi Sankyo Company?
Daiichi Sankyo Company has 18,726 total employees.
-
What industry is Daiichi Sankyo Company in?
Daiichi Sankyo Company’s primary industry is Biotechnology.
-
Is Daiichi Sankyo Company a private or public company?
Daiichi Sankyo Company is a Public company.
-
What is Daiichi Sankyo Company’s stock symbol?
The ticker symbol for Daiichi Sankyo Company is 4568.
-
What is the current stock price of Daiichi Sankyo Company?
As of 07-Feb-2025 the stock price of Daiichi Sankyo Company is $25.35.
-
What is the current market cap of Daiichi Sankyo Company?
The current market capitalization of Daiichi Sankyo Company is $47.7B.
-
What is Daiichi Sankyo Company’s current revenue?
The trailing twelve month revenue for Daiichi Sankyo Company is $11.9B.
-
Who are Daiichi Sankyo Company’s competitors?
Astellas Pharma, Celldex Therapeutics, Genmab, Immatics, and Enzon Pharmaceuticals are some of the 57 competitors of Daiichi Sankyo Company.
-
What is Daiichi Sankyo Company’s annual earnings per share (EPS)?
Daiichi Sankyo Company’s EPS for 12 months was $0.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
